Empower Clinics Inc.

Empower Clinics Inc.

EPWCF
Empower Clinics Inc.US flagOther OTC
0.00
USD
- -
- -
2.54MMarket Cap
Empower Clinics Inc.
EPWCF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
FRC
- -
- -
- -
- -
1.09
0.99
1.07
0.01
- -
- -
- -
- -
0.08
0.09
0.09
0.07
0.08
Revenue per Share
-0.13
-0.08
-0.91
-3.89
-2.43
-7.13
-5.96
-2.34
0.3
-0.09
-0.06
-0.02
-0.28
-0.18
-0.47
-0.49
-0.13
Basic EPS, GAAP
-0.09
-0.1
-0.69
-1.02
-2.39
-5.74
-8.33
-1.93
-0.16
-0.13
-0.03
-0.01
-0.22
-0.1
-0.05
-0.09
-0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.64
-9.33
-10.25
-3.89
-4.07
-14.4
-16.34
-14.35
-13.93
-11.05
-10.04
-10.06
-0.3
-0.22
-0.19
-0.14
-0.13
Book Value per Share
4.96
4.23
3.43
7.45
1.44
6.63
2.83
-0.24
0.08
-0.02
-0.08
-0.11
-0.23
-0.17
-0.22
-0.1
-0.08
Tangible Book Value per Share
- -
- -
- -
- -
1
1
2
2
2
3
3
3
13
23
36
66
69
Basic Weighted Avg Shares
- -
- -
- -
- -
1
1
2
- -
- -
- -
- -
- -
1
2
3
4
5
Sales/Revenue/Turnover
- -
- -
- -
- -
-221.32
-635.3
-235.1
-20,429.41
- -
- -
- -
- -
-514.77
-173.02
-110.95
-123.75
-105.94
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Depreciation Expense
- -
- -
- -
-1
-2
-9
-11
-6
1
- -
- -
- -
-4
-4
-17
-32
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
-222.78
-717.23
-558.87
-33,200
- -
- -
- -
- -
-347.26
-211.74
-531.79
-738.31
-170.89
Profit Margin (%)
1
1
1
2
1
8
1
-1
- -
- -
- -
- -
-3
-4
-2
-5
-3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
4
4
LT Debt
1
1
1
3
1
9
5
-1
- -
- -
- -
- -
-3
-4
-5
-6
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
307.93
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
-2.15
- -
- -
- -
- -
- -
- -
- -
401.12
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
1
1
1
LT Borrowings
2
2
2
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
70
70
70
Market Capitalization
61
26
- -

Working Capital

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
4
3
2
Cash, Cash Equivalents & STI
3
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
9
5
5
Payables & Accruals
4
3
4
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.28%
167.81%
16.44%
Free Cash Flow
851.99%
1,731.4%
228.83%
Net Income, GAAP
498.24%
1,057.47%
89.01%
Sales/Revenue/Turnover
- -
- -
36.14%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
1
- -
- -
1
3
2021
2
1
- -
1
4
2022
1
2
2
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.02
-0.01
-0.01
- -
-0.47
2021
-0.42
-0.01
-0.03
- -
-0.49
2022
-0.03
0.03
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Business
Empower Clinics Inc. (EPWCF) operates as an integrated healthcare company that provides body and mind wellness services to patients through medical clinics, digital and telemedicine care, and medical diagnostics laboratories in the United States and Canada; the company also distributes medical devices via subsidiaries including Kai Medical Canada Corp. and MediSure. Its core offerings encompass clinic operations and patient visits under the Health & Wellness segment; diagnostic testing services through Kai Medical and medical equipment sales under the Diagnostics & Technology segment; and clinical trial services such as trial design, patient recruitment, data management, and regulatory compliance for pharmaceutical, biotechnology, and medical device industries, supported by two clinical research sites in Dallas, Texas, functioning as a site management organization (SMO) with six principal investigators overseeing multiple trials under application. Founded in 1997 and headquartered at 1771 Robson Street, Suite 505, Vancouver, British Columbia, V6G 1C9, Canada, Empower Clinics targets patients seeking preventative, diagnostic, and treatment services with a focus on patient experience across North American markets. Recent developments include the announcement of a CAD$2 million share offering and closing of a first tranche private placement financing; a lab services contract with Specialist Network of North America; signing of new agreements with two additional principal investigators to advance research and clinical trials; proposals for private placements of debenture and share units; a partial revocation of a cease trade order to facilitate compliance and private placements up to 24.4 million units; resignations of two directors; and plans for a proposed spin-out of its healthcare AI division to enhance clinical trial participant identification and recruitment.

Company News

APIChatGPT
  • Empower Clinics Provides Corporate Update

  • Empower Clinics Announces Closing of Second Tranche Private Placement Financing

  • Empower Clinics Announces Closing of First Tranche Private Placement Financing

  • Empower Clinics Announces Proposal For Division Spin Out

  • Empower Clinics Signs New Agreements To Advance Growth Of Research and Clinical Trials with Signing Of Two Additional Principal Investigators - And Are Approved To Process Multiple Clinical Study Applications From Pharmaceutical Sponsors

  • Empower Clinics signs letter of intent for equity capital facility

  • Empower Clinics looks to expand research opportunities, utilize financial advisor to grow shareholder value

  • Empower Clinics signs fourth principal investigator for Dallas site

  • Empower Clinics adds two new researchers to support clinical trials services at its site in Dallas

  • Empower Clinics signs clinical trials services deal with Texas medical group

  • Empower Clinics commences process to explore and evaluate strategic options

  • Empower Clinics advances partnership to launch US clinical trial management services

  • Empower Clinics ends Q4 2022 with $193,144 in cash; continues to focus on clinical trial services

  • Empower Clinics partners with nuclear medicine specialist to launch US clinical trial management services

  • Empower Clinics announces partnership with Fobi AI unit to elevate investor relations with digital, mobile and personalized engagement

  • Empower Clinics says subsidiary MediSure's diabetes test strips get OK for government programs

  • Empower Clinics announces an offering of units at a price of 3 cents each for aggregate gross proceeds of between $2M and $5M

  • Empower Clinics consolidates three medical clinics to focus on flagship Etobicoke integrated medical clinic

  • Empower Clinics says MediSure Laboratory signs laboratory services agreement with Alp MedTech AG

  • Empower Clinics taps Zeifmans LLP as new auditor as it boosts accounting and financial controls